There was a problem sending you an sms. Check your phone number or try again later.
We've sent a link to the Scribd app. If you didn't receive it, try again.
An experimental, but promising, therapy aimed at improving vision in people with
macular degeneration is being tested in a local study, allowing participants to get the drug
while it's being reviewed by the Food and Drug Administration.
Lucentis \u2014 which has been found during earlier clinical trials to stabilize vision in 90%
of patients and improve vision in 60% of them \u2014 is being offered at Retina-Vitreous
Associates on the Baptist Hospital campus.
"This drug is the first treatment to show significant improvement of vision," said Dr. Carl
C. Awh, with Retina-Vitreous Associates. "Up to now, all we've been able to promise
them is less of a loss of vision."
The therapy is used to treat one specific type of macular degeneration, known as wet
macular degeneration. Awh said the study is accepting a few dozen participants, who may
call Retina-Vitreous Associates at 320-7911 for more information.
To be eligible, people must be in the early stages of macular degeneration, without
complete central vision loss. The treatment involves injecting Lucentis directly into the
eye. Earlier studies have shown that there are risks of mild side effects, including
discomfort and redness at the injection site and infection.
Now bringing you back...
Does that email address look wrong? Try again with a different email.